Today: 9 June 2026
Browse Category

NASDAQ:NFE 29 October 2025 - 15 December 2025

New Fortress Energy (NFE) Stock Today (Dec. 15, 2025): Debt Deadline, Puerto Rico Contract, and Analyst Forecasts Collide

New Fortress Energy (NFE) Stock Today (Dec. 15, 2025): Debt Deadline, Puerto Rico Contract, and Analyst Forecasts Collide

New Fortress Energy shares traded near $1.26 Monday, down 2.3%, as the company faces a December 15 deadline tied to a forbearance agreement on missed interest payments for its 2029 Notes. The agreement covers holders of over 70% of the notes and could trigger acceleration of debt if not extended or restructured. The stock sits near its 52-week low after a year of heavy volatility. Investors remain focused on debt negotiations.
15 December 2025
·
New Fortress Energy (NFE) Stock: Puerto Rico Gas Deal Triggers Relief Rally Amid Going‑Concern Fears – December 5, 2025

New Fortress Energy (NFE) Stock: Puerto Rico Gas Deal Triggers Relief Rally Amid Going‑Concern Fears – December 5, 2025

New Fortress Energy shares jumped in pre-market trading December 5 after final approval of a 7-year LNG supply deal with Puerto Rico. The stock closed at $1.40, up to $1.56 pre-market, but remains down over 90% from its 52-week high. The company faces “substantial doubt” about its ability to continue as a going concern and is restructuring $7–9 billion in debt. Market cap stands at $400 million.
5 December 2025
·
New Fortress Energy (NFE) Whipsaws as Fitch Slaps ‘RD’ Rating, Q3 Loss Nears $300 Million and Debt Clock Ticks Toward December 15

New Fortress Energy (NFE) Whipsaws as Fitch Slaps ‘RD’ Rating, Q3 Loss Nears $300 Million and Debt Clock Ticks Toward December 15

New Fortress Energy reported a Q3 2025 net loss of $300 million as revenue fell to $327 million and interest expense tripled to $210.6 million. The company missed a November 17 interest payment, triggering a Fitch downgrade to ‘Restricted Default’. A forbearance deal extends the payment deadline to December 15. Shares jumped over 20% after a key debt amendment eased short-term pressure.
21 November 2025
·
New Fortress Energy Seeks U.K. Lifeline to Dodge Bankruptcy – Shares Crash as $9 B Debt Weighs

New Fortress Energy (NFE) Cut to ‘Restricted Default’ as Debt Stress Deepens – What Today’s Fitch Downgrade Means for the Stock

Fitch Ratings downgraded New Fortress Energy to “Restricted Default” after the company missed a November 15 interest payment on $2.7 billion in senior secured notes. NFE entered a 30-day forbearance with creditors and delayed its Q3 financial filing. S&P cut its rating to “Selective Default” earlier this week. Shares closed up 26% at $1.46 on heavy trading.
20 November 2025
··
New Fortress Energy Seeks U.K. Lifeline to Dodge Bankruptcy – Shares Crash as $9 B Debt Weighs

New Fortress Energy’s Wild Ride: 90% Crash, Debt Drama & a Surprise Rally – What’s Next for NFE Stock?

New Fortress Energy shares plunged over 90% year-to-date, closing at $1.18 on Nov. 3, before rebounding 32% in pre-market trading. The drop accelerated after reports of a UK debt restructuring plan to address $9 billion in liabilities and avoid U.S. bankruptcy. NFE faces “going concern” warnings ahead of Q3 earnings on Nov. 6, with analysts expecting another loss. The stock remains volatile amid contract wins and heavy downgrades.
4 November 2025
··
New Fortress Energy Seeks U.K. Lifeline to Dodge Bankruptcy – Shares Crash as $9 B Debt Weighs

New Fortress Energy Seeks U.K. Lifeline to Dodge Bankruptcy – Shares Crash as $9 B Debt Weighs

New Fortress Energy is weighing a U.K. “scheme of arrangement” to restructure about $9 billion in debt, aiming to avoid U.S. Chapter 11 bankruptcy. Shares plunged 8% Wednesday, extending a 90% year-to-date drop, as investors reacted to mounting bankruptcy fears. Moody’s downgraded NFE to Caa1 in March, citing weak liquidity and high leverage. Bondholders have organized to negotiate as the company seeks a global debt deal.
29 October 2025
···

Stock Market Today

  • Nuvalent Shares Surge Near $124 Following GSK's $10.6 Billion Buyout Offer
    June 9, 2026, 10:35 AM EDT. Nuvalent's stock jumped 38.9% to $122.93 after GSK announced a $10.6 billion cash acquisition at $124 per share, reflecting a 40% premium to the last close. The deal highlights GSK's strategic move to expand its oncology portfolio beyond its current 6% share of sales, aiming to capitalize on Nuvalent's two lung cancer drugs pending FDA decisions this year. The tender offer needs the approval of at least half of Nuvalent's Class A shares and U.S. antitrust clearance. Early analyst reactions included target price adjustments but echoed caution over valuation. Nuvalent's pipeline products could face competition from existing ALK-targeted therapies by Pfizer and Roche.

Latest articles

Autozi Shares Jump 400%, Filing Flags Risks for AZI

Autozi Shares Jump 400%, Filing Flags Risks for AZI

9 June 2026
Autozi Internet Technology shares soared over 400% to $5.69 in early Nasdaq trading after a 10-for-1 share consolidation slashed its share count to about 4.49 million, but the surge contrasts with a 63.1% revenue drop, 82.5% plunge in gross profit, and widened net loss, with the company warning of “substantial doubt” about its ability to continue as a going concern.
Redwire Shares Slip After $500 Million Stock Offering Filed

Redwire Shares Slip After $500 Million Stock Offering Filed

9 June 2026
Redwire Corp shares plunged 6.5% to $17.37 after launching a $500 million at-the-market stock program, raising dilution risks for investors as the company seeks flexible funding despite recent record backlog and strong revenue growth; the drop contrasted with gains at other space stocks, highlighting investor concern over potential share issuance.
Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

9 June 2026
Nuvalent shares soared 38.9% to $122.93, just below GSK’s $124-a-share cash offer after the $10.6 billion buyout was announced, as investors bet on the deal closing with Nuvalent’s two lead lung-cancer drugs already under FDA review and a 40% premium to the last closing price driving the morning’s merger-arb trade.
Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
Go toTop